Literature DB >> 11831646

Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies.

L A Hazlehurst1, W S Dalton.   

Abstract

The tumor microenvironment is often overlooked when considering tumor response to chemotherapeutic agents. This environment consists of soluble factors, components of the extracellular matrix as well as cell-cell interactions. Recently, it has become clear that cell-cell and cell-matrix interactions result in cytoskeletal reorganization and the activation of multiple signal transduction pathways that directly influence cell survival, growth and differentiation. Experimental evidence shows that anti-apoptotic pathways initiated by cell adhesion are operative in tumor cells and, furthermore, cause resistance to mechanistically distinct cytotoxics. For hematopoietic tumors, cell adhesion to a single matrix, fibronectin is sufficient to inhibit apoptosis induced by mechanistically distinct cyctotoxics. Adhesion of hematopoietic tumors to this matrix blocks cell cycle progression, and for the human multiple myeloma 8226 cell line adhesion to fibronectin resulted in increased p27kip1 levels, which correlated with cell cycle arrest and drug resistance. A decrease in initial DNA damage induced by topoisomerase II inhibitors has also been observed in adherent hematopoietic tumor cell lines. Further studies investigating the mechanisms of cell adhesion mediated drug resistance may reveal novel targets directed at the reversal of de novo drug resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11831646     DOI: 10.1023/a:1013156407224

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  72 in total

1.  Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

Authors:  Chad C Bjorklund; Wencai Ma; Zhi-Qiang Wang; R Eric Davis; Deborah J Kuhn; Steven M Kornblau; Michael Wang; Jatin J Shah; Robert Z Orlowski
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

Review 2.  [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].

Authors:  J M Löhr; R Faissner; P Findeisen; M Neumaier
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

3.  Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness.

Authors:  Liat Nadav; Vyacheslav Kalchenko; Meir Max Barak; Elizabeth Naparstek; Benjamin Geiger; Ben-Zion Katz
Journal:  Exp Hematol       Date:  2008-08-09       Impact factor: 3.084

Review 4.  Nanomedicine therapeutic approaches to overcome cancer drug resistance.

Authors:  Janet L Markman; Arthur Rekechenetskiy; Eggehard Holler; Julia Y Ljubimova
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

Review 5.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

6.  A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR.

Authors:  Elizabeth Monaghan-Benson; Cynthia Corley Mastick; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

7.  Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4.

Authors:  Yohei Saito; Toshiyuki Owaki; Takuya Matsunaga; Mizue Saze; Shogo Miura; Mao Maeda; Mayu Eguchi; Rika Tanaka; Junichi Taira; Hiroaki Kodama; Sumio Goto; Yoshiroh Niitsu; Hiroshi Terada; Fumio Fukai
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

Review 8.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

9.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

10.  Transfection of myeloid leukaemia cell lines is distinctively regulated by fibronectin substratum.

Authors:  Gunes Esendagli; Hande Canpinar; A Lale Dogan; Munir Akkaya; Emin Kansu; Dicle Guc
Journal:  Cytotechnology       Date:  2009-12-06       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.